Comparison of the hemodynamic stability of remimazolam versus dexmedetomidine during ultrasound-guided radiofrequency ablation of hepatic tumor under monitored anesthesia care

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0007244

Enrollment

Registered

2022-04-29

Start date

2022-05-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In the dexmedetomidine group, a loading dose of 1 mg/kg of dexmedetomidine is administered for 10 minutes, followed by administration at a rate of 0.3-0.7 mg/kg/h to maintain sedation. During s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing ultrasound-guided percutaneous liver radiofrequency ablation under monitored anesthesia care

Exclusion criteria

Exclusion criteria: 1. Patients with a history of drug allergy to dexmedetomidine, benzodiazepine, or opioid analgesics 2. Patients with contraindications to dexmedetomidine, remimazolam, or remifentanil 3. Patients with body classification 3 or higher by the American Society of Anesthesiologists Physical Status 4. Patients with a body mass index of 35 or higher 5. Child-Pugh class C cirrhosis 6. Patients undergoing dialysis for end-stage renal disease 7. Patients scheduled for RFA under general anesthesia 8. Patients judged to be inappropriate by other researchers

Design outcomes

Primary

Measure	Time frame
Composite incidence of bradycardia and hypotension	—

Secondary

Measure	Time frame
total remifentanil dose ;awakening time;post-anesthesia care unit stay time	—

Countries

Korea, Republic of

Contacts

Public ContactGo Wun Kim

Asan Medical Center

fungid@paran.com+82-2-3010-3868

Outcome results